1 infusion was randomized, counterbalanced and
single blinded.
2 In this prospective,
single-blinded,
1:1 randomized trial, we enrolled 330 pa
3 October 2005 and August 2008, we conducted a
single-blind,
12-month, randomized controlled trial of t
4 disorder received placebo intranasal spray (
single-blind)
15 minutes before laboratory-simulated pub
5 ntidepressant administration, we performed a
single-blinded 2-week crossover randomized clinical tria
6 cale registry-based randomized, multicenter,
single-blind,
2-arm, noninferiority trial-compared 2 bio
7 le, registry-based, randomized, multicenter,
single-blind,
2-arm, noninferiority trial.
8 en) participated in two separate randomized,
single-blind,
2-day protocols.
9 Prospective, randomized,
single-blind,
24-week study with blinded end point asses
10 A
single-blind,
3-arm, randomized controlled trial was con
11 In this pragmatic,
single-blind,
3-arm, randomized trial (SMS-Text Adherenc
12 12-week,
single-blind,
3-group randomized noninferiority trial an
13 In this randomized, international, 2-center,
single-blinded,
3-arm study, STEMI patients were randoml
14 After a
single-blind,
4-5-week placebo run-in period, 332 patien
15 After a
single-blind,
4-week placebo run-in, patients were rando
16 receive rapamycin or methotrexate (MTX) in a
single-blind,
48-week study.
17 The TS-134 trial was a randomized,
single-blind,
6-day study of 20 or 60 mg/d TS-134 versus
18 In a randomized
single-blind 8-week study, patients with clozapine-resis
19 On 2 measurement days, subjects consumed
single-blinded a plain low-fat yogurt or low-fat yogurt
20 OUT IV) trial was a randomized multicenter,
single-blind,
all-comer, 2-arm, noninferiority trial com
21 ries; n=1398) is a prospective, multicenter,
single-blinded,
all-comers, randomized controlled trial
22 In a
single-blinded and placebo-controlled crossover study of
23 e randomized and nonrandomized double-blind,
single-blind,
and open-label clinical trials of any phar
24 on groups and treatment methods, be at least
single-blinded,
assess biologic mechanisms, have adequat
25 In this
single-blind case-crossover study, 41 healthy subjects u
26 rt the outcome of the first cross-sectional,
single-blind clinical performance evaluation of a urine
27 , AND PARTICIPANTS: Multicenter, randomized,
single-blind clinical trial conducted between October 20
28 -mo, randomized, positive-comparator, 2-arm,
single-blind clinical trial in 211 patients treated with
29 In this randomized,
single-blind clinical trial, we randomly assigned childr
30 TIENTS: Multicenter, randomized, controlled,
single-blinded clinical trial based on the Iron (Fe) and
31 For this randomized,
single-blinded clinical trial, children aged 6-59 months
32 Randomized,
single-blind,
clinical trial among 217 dyads (1 parent:
33 tting, and Participants: Phase 3 randomized,
single-blind,
clinical trial conducted from March 1, 201
34 A community-based
single-blind cluster-randomized controlled superiority t
35 In a
single-blind,
cluster, randomised, controlled trial, 34
36 In this 6-center,
single-blinded,
cluster-randomized, controlled trial, pr
37 In a
single-blind,
code-based, placebo-controlled, counterbal
38 This
single-blind,
community-based, randomized clinical trial
39 Donors were randomized to receive, in a
single-blind controlled fashion, 600 mg of intravenous N
40 In a
single-blind controlled prospective study of 60 patients
41 This was a parallel-group, randomized,
single-blind controlled trial carried out in an intellec
42 MATERIALS/METHODS: A randomised
single-blind controlled trial of IIV in autoHCT patients
43 , AND PARTICIPANTS: Prospective, randomized,
single-blind,
controlled study conducted in 54 centers i
44 This is a prospective, randomized (1:1),
single-blind,
controlled trial comparing outcomes of pat
45 SPIRIT III trial, a prospective, randomized,
single-blind,
controlled trial enrolling patients at 65
46 study is an ongoing prospective, randomized,
single-blind,
controlled trial in 1,002 coronary heart d
47 nvestigator-driven, multicenter, randomized,
single-blind,
controlled trial randomized ST-segment-ele
48 NG, AND PATIENTS: A prospective, randomized,
single-blinded,
controlled trial of 1161 patients presen
49 al across subjects/groups, except that, in a
single-blind,
counterbalanced design, CD received intrav
50 Following a
single blind,
cross-over and non-randomized design we in
51 We performed a
single blind,
cross-over study involving 12 CD patients
52 oral glucose tolerance test in a randomized,
single-blind,
cross-over design in 15 healthy lean men.
53 In a
single-blind,
cross-over study, 10 trained cyclists (age
54 We performed a randomized,
single-blind,
cross-over study, with 2 study visits 4 we
55 ustralian diet, in a randomized, controlled,
single-blind,
cross-over trial of patients with IBS.
56 In a separate randomized,
single-blind,
cross-over validation study, 6 additional
57 s lorazepam (LRZ; 0.01 mg/kg) or saline in a
single-blinded,
cross-over design (two sessions separate
58 ement doses" of leptin (Wt(-10%leptin)) in a
single-blind crossover design with a 2-wk washout period
59 ncluded in a randomized, placebo-controlled,
single-blind crossover study and compared with 12 health
60 In a randomized,
single-blinded crossover study, 12 healthy white men [me
61 In this
single-blinded crossover trial, 50 patients with RA were
62 Using a prospective, randomized,
single-blind,
crossover study design, we therefore measu
63 of EGP, eight healthy men were studied in a
single-blind,
crossover study with two randomized visits
64 In a prospective, single-center,
single-blind,
crossover study, 56 patients with non-ST-e
65 stural tachycardia syndrome in a randomized,
single-blind,
crossover study.
66 kg/m(2)) of 24.3 +/- 4.4 were enrolled in a
single-blind,
crossover, randomized controlled trial.
67 Two groups of participants were tested in a
single-blind design.
68 asions according to a randomized, crossover,
single-blinded design.
69 We performed a randomized, parallel,
single-blind dose-ranging phase 2 trial in the Lao Peopl
70 A
single-blind,
dose-dependent, parallel randomized contro
71 In a monocenter, placebo-controlled,
single-blind,
dose-escalation pilot study, 18 subjects w
72 In this phase 2,
single-blind,
dose-ranging, adaptive randomised trial, w
73 In this 104-week, randomised,
single-blind (
double-blind until week 12 and investigato
74 This study was a prospective,
single-blinded,
education research study of 48 neurology
75 DESIGN, SETTING, AND PARTICIPANTS:
Single-blind effectiveness trial at 7 university-based a
76 This prospective,
single blinded (
endoscopist), randomized controlled tria
77 MORE CARE was a multicentre,
single-blind,
factorial, randomised controlled trial in
78 implant, subjects were randomly assigned in
single-blind fashion to a treatment group in whom daily
79 ng artificial sweeteners (n = 10) were given
single-blind in a 10-wk parallel design.
80 In this
single-blind,
individually randomised controlled trial,
81 Single-blind low-dose (n = 42), high-dose (n = 40), or p
82 luated using banked specimens collected in a
single-blind manner and yielded a clinical sensitivity a
83 In a prospective, randomized,
single-blind,
multicenter study, 141 patients with sympt
84 as a secondary analysis of a North American,
single-blind,
multicenter, cluster-randomized, clinical
85 In this prospective,
single-blind,
multicenter, randomized trial, the authors
86 We did a prospective, randomised,
single-blind,
multicentre study (TALENT) across 23 centr
87 We did a randomised,
single-blind,
multicentre, phase 3 study (DESSOLVE III)
88 We undertook a
single-blind,
multicentre, randomised controlled trial i
89 In a
single-blind,
multicentre, randomised trial, we enrolled
90 SCIENCE trial was an investigator-initiated,
single-blind,
multicentre, randomized, noninferiority tr
91 CHAMPION trial was a prospective, parallel,
single-blinded,
multicentre study that enrolled particip
92 In this phase 2b,
single-blind,
non-inferiority trial (CLARITY), adults (a
93 Randomized,
single-blind noninferiority trial conducted between the
94 (A Prospective Randomized Multicenter
Single-Blind Noninferiority Trial to Assess the Safety a
95 We performed a
single-blinded noninferiority trial to compare periopera
96 SIGN, SETTING AND PARTICIPANTS: Multicenter,
single-blind,
noninferiority randomized clinical trial c
97 the EVOLVE study, a prospective, randomized,
single-blind,
noninferiority trial.
98 ouble-blind) and fruit and vegetable intake (
single-blind)
on bone turnover over 2 y.
99 lusters) in Burkina Faso to participate in a
single-blind (
outcomes assessor), parallel-assignment, t
100 ticenter randomized controlled trial, with a
single-blind parallel design, was conducted between 2006
101 Single-blinded parallel-group randomized trial at 12 int
102 A prospective, placebo-controlled,
single-blind,
parallel group study was carried out inclu
103 ANTS: A single-center, 18-month, randomized,
single-blind,
parallel group trial enrolled 60 low-funct
104 riority, three-arm, individually randomised,
single-blind,
parallel group trial, patients were recrui
105 prospective, randomised, active-controlled,
single-blind,
parallel two-group, multicentre clinical t
106 In this
single-blind,
parallel, controlled, dietary intervention
107 In this
single-blind,
parallel, group randomised controlled tria
108 METHODS AND In this
single-blind,
parallel, randomised controlled trial, adu
109 andomized to one of four dose groups in this
single-blind,
parallel, randomized, control trial.
110 This was a
single-blind,
parallel-assignment randomized controlled
111 was a prospective, multicenter, randomized,
single-blind,
parallel-controlled trial of 274 New York
112 In a randomized, controlled,
single-blind,
parallel-group dietary intervention, 195 m
113 SIGN, SETTING, AND PARTICIPANTS: Randomized,
single-blind,
parallel-group trial that enrolled 1902 pr
114 In this randomised, controlled,
single-blind,
parallel-group trial we enrolled adults (a
115 We performed a
single-blinded,
parallel-group, randomized controlled tr
116 Design:
Single-blinded,
parallel-group, randomized trial.
117 ession (leuprolide) then received 1 month of
single-blind (
participant only) placebo and then 3 month
118 We did a multicentre,
single-blind,
patient-level, parallel, randomised contro
119 54 (0.018 mg/kg) for 6 consecutive days in a
single-blind (
patients masked), placebo-controlled study
120 A randomized
single-blind phase 2 clinical drug trial conducted betwe
121 ised, parallel-group, comparator-controlled,
single-blind phase 3 trial, we assessed the efficacy of
122 rus vaccine, ChAdOx1 nCoV-19 (AZD1222), in a
single-blinded phase 1/2 randomized controlled trial of
123 We did this
single-blind,
phase 2, randomised controlled trial (SUPE
124 The antidepressant lead-in employing
single-blind placebo and the sequential-parallel compari
125 optimise risk factor and glycaemic control (
single-blind placebo in the final month).
126 trials (50%) than a phase 3 program using a
single-blind placebo lead-in (40%).
127 After a 4-week,
single-blind placebo run-in period, participants were ra
128 After a 2-week
single-blind placebo run-in period, patients were random
129 e eating scale scores >/= 19 received 1-week
single-blind placebo run-in, and were then randomized to
130 or 24 months followed by a 2-month period of
single-blind placebo treatment.
131 One-week
single-blind placebo was followed by randomized double-b
132 ek treatment period was followed by a 6-week
single-blind placebo washout period.
133 In part 2, after a 4-week,
single-blind placebo washout, continuing subjects were r
134 After one menstrual cycle of
single-blind placebo, participants were randomized to re
135 In a
single-blind placebo-controlled cross-over design, all p
136 autonomic dysfunction and inflammation in a
single-blind placebo-controlled crossover pilot trial.
137 e on antioxidant and glucose parameters in a
single-blind placebo-controlled crossover study was inve
138 Single-blind placebo-controlled DPT was carried out in t
139 After confirming the diagnosis, a
single-blind placebo-controlled drug provocation test wa
140 Skin tests (STs) and
single-blind placebo-controlled drug provocation tests (
141 placebo augmentation, followed by 2 weeks of
single-blind placebo.
142 ast 2 weeks, eszopiclone was replaced with a
single-blind placebo.
143 treatment periods were followed by a 14-day
single-blinded placebo follow-up period.
144 Study 1 (n = 17) was a 2-wk
single-blinded placebo pill trial.
145 A
single-blinded placebo-controlled design was used to mas
146 ice daily) for 12 weeks, following a 2-week,
single-blind,
placebo run-in period.
147 s per day]) were randomized (after a 3-week,
single-blind,
placebo, run-in period) to 1 of 3 parallel
148 on in HE after capsular FMT in a randomized,
single-blind,
placebo-controlled clinical trial in Virgi
149 This investigator-initiated, multicenter,
single-blind,
placebo-controlled crossover clinical tria
150 In this
single-blind,
placebo-controlled crossover study, 16 par
151 Single-blind,
placebo-controlled oral provocation tests
152 Single-blind,
placebo-controlled provocation tests (SBPC
153 n this multicentre phase 1b, first-in-human,
single-blind,
placebo-controlled trial, we randomly assi
154 We performed a 9-visit, randomized,
single-blind,
placebo-controlled, 2-way crossover study
155 METHODS AND This was a
single-blind,
placebo-controlled, crossover, randomized
156 This was a
single-blind,
placebo-controlled, crossover, randomized
157 We did a
single-blind,
placebo-controlled, dose-escalation study
158 This was a randomized,
single-blind,
placebo-controlled, parallel-group study o
159 We did a randomised,
single-blind,
placebo-controlled, phase 1 dose-escalatio
160 We did this randomised,
single-blind,
placebo-controlled, phase 2 trial at 25 si
161 Then, we performed a
single-blind,
placebo-controlled, within-subject human s
162 A randomized,
single-blinded,
placebo-controlled trial was performed o
163 Seventeen healthy subjects participated in a
single-blinded,
placebo-controlled, 2 x 2 crossover tria
164 METHODS AND A
single-blind,
pragmatic randomised controlled trial (RCT
165 We did a
single-blind,
pragmatic, comparative effectiveness, clus
166 was an investigator initiated single-center,
single-blind prospective, randomized controlled trial wi
167 : This randomized
single-blinded prospective trial allocated 20 surgical t
168 This
single-blinded prospective trial randomized 16 novice su
169 Phase 3
single-blind,
prospective randomized controlled trial, 1
170 We did a single centre,
single-blind,
prospective, randomised pilot trial at the
171 We conducted a
single-blind,
prospective, randomized trial with 128 men
172 measurements were repeated on a placebo day (
single-blind protocol, randomized sequence).
173 0 mg over 30 min) on separate occasions in a
single-blind,
random order, crossover design.
174 We did a
single-blind randomised controlled trial at two UK centr
175 A
single-blind randomised trial of the comparison of 12 se
176 In this
single-blind randomised trial, we enrolled consecutive a
177 A phase IV, 12-month,
single-blinded randomised (MRI) study.
178 ational investigator-initiated, prospective,
single-blind,
randomised controlled trial (CONDI-2/ERIC-
179 We did this
single-blind,
randomised controlled trial (OASIS) at 26
180 We did this
single-blind,
randomised controlled trial at a single cl
181 In this
single-blind,
randomised controlled trial done at two sp
182 We did a phase 1/2,
single-blind,
randomised controlled trial in five trial
183 In COMMAND, a
single-blind,
randomised controlled trial, eligible part
184 In this cluster-design,
single-blind,
randomised controlled trial, we included g
185 In this parallel, multicentre,
single-blind,
randomised controlled trial, we included p
186 In the phase 1,
single-blind,
randomised trial of ChAd3-EBO-Z in the USA
187 In this
single-blind,
randomised trial, undertaken in the UK, sm
188 We did a multicentre,
single-blind,
randomised, controlled trial with follow-u
189 EQoL-MDS was a
single-blind,
randomised, controlled, phase 2 superiorit
190 In this report of the phase 2 component of a
single-blind,
randomised, controlled, phase 2/3 trial (C
191 In this
single-blind,
randomised, multicentre, non-inferiority t
192 We did a phase 1,
single-blind,
randomised, placebo-controlled trial to as
193 TN-OFF MED was a multicentre, international,
single-blind,
randomised, sham-controlled, proof-of-conc
194 We did a multicentre,
single-blinded,
randomised controlled trial at 15 tertia
195 We did a multicentre,
single-blinded,
randomised controlled trial at six centr
196 Single-blind randomization to insertion of 2 gentamicin-
197 We performed a
single-blind randomized clinical trial from April 24, 20
198 A
single-blind randomized clinical trial with 3 arms (N =
199 In this
single-blind randomized clinical trial, 8003 adults with
200 Single-blind randomized clinical trial, conducted betwee
201 A
single-blind randomized controlled clinical trial was co
202 In this
single-blind randomized controlled trial, participants w
203 A
single-blind randomized crossover design was used.
204 ts of cycling at ventilatory threshold, in a
single-blind randomized manner, while breathing: (i) nor
205 Using a
single-blind randomized study design, we experimentally
206 Phase 3, pragmatic,
single-blind randomized trial among 361 participants wit
207 Single-blind randomized trial conducted from February 20
208 In this large-scale, prospective,
single-blind randomized trial, a novel PtCr-EES was noni
209 The authors conducted a
single-blinded randomized clinical trial and assigned a
210 This study is a
single-blinded randomized clinical trial.
211 This prospective,
single-blinded randomized controlled trial allocated 25
212 A
single-blinded randomized controlled trial in children (
213 This prospective
single-blinded randomized trial allocated 24 surgical re
214 The TRYTON (Prospective,
Single Blind,
Randomized Controlled Study to Evaluate th
215 (Prospective,
Single Blind,
Randomized Controlled Study to Evaluate th
216 We performed a
single blind,
randomized, controlled trial in Cote d'Ivo
217 An institutional review board-approved,
single blinded,
randomized controlled trial was conducte
218 N, SETTING, AND PARTICIPANTS: Cluster-based,
single-blind,
randomized clinical trial at 15 sites in 8
219 was an investigator-initiated, multicenter,
single-blind,
randomized clinical trial conducted at 5 r
220 SIGN, SETTING, AND PARTICIPANTS: A 12-month,
single-blind,
randomized clinical trial conducted from A
221 DESIGN, SETTING, AND PARTICIPANTS: A
single-blind,
randomized clinical trial of 61 adolescent
222 Design, Setting, and Participants: A
single-blind,
randomized clinical trial of ED-initiated
223 ssages (TEXT ME) trial was a parallel-group,
single-blind,
randomized clinical trial that recruited 7
224 A multicenter,
single-blind,
randomized clinical trial was conducted fr
225 The objective of this multisite,
single-blind,
randomized clinical trial was to test whet
226 The aim of this study was to conduct a
single-blind,
randomized controlled intervention trial w
227 n intensive care units [ICUs]), prospective,
single-blind,
randomized controlled trial involving 400
228 DESIGN, SETTING, AND PARTICIPANTS: A
single-blind,
randomized controlled trial of 25 US healt
229 We conducted a prospective,
single-blind,
randomized controlled trial of 40 individu
230 A
single-blind,
randomized controlled trial was conducted.
231 The authors performed a multicenter,
single-blind,
randomized controlled trial.
232 The study design was a parallel-group,
single-blind,
randomized controlled trial.
233 cebo for 28 d with the use of a dual-center,
single-blind,
randomized crossover design.
234 The study was a 14-wk,
single-blind,
randomized crossover dietary trial with tw
235 In this
single-blind,
randomized trial conducted at 54 sites, we
236 We conducted a
single-blind,
randomized trial of classic Yang-style tai
237 We conducted two
single-blind,
randomized trials comparing a genotype-gui
238 s with obesity underwent 2 MRI sessions in a
single-blind,
randomized, case-controlled crossover stud
239 The study was an 8-wk,
single-blind,
randomized, controlled isocaloric trial wi
240 We conducted a
single-blind,
randomized, controlled trial in 14 primary
241 In a
single-blind,
randomized, crossover study, 10 insulin-re
242 A
single-blind,
randomized, placebo-controlled study was c
243 MTN-027, a
single-blind,
randomized, placebo-controlled trial in 48
244 We designed a prospective,
single-blind,
randomized, sham-controlled trial.
245 Patients (CHAMPION) trial was a prospective,
single-blinded,
randomized controlled clinical trial tes
246 present study, we used a placebo-controlled,
single-blinded,
randomized cross-over design to test the
247 Using a placebo-controlled,
single-blinded,
randomized cross-over design, we tested
248 ACT SFA Trial is a prospective, multicenter,
single-blinded,
randomized trial in which 331 patients w
249 We performed a
single-blinded,
randomized trial to determine whether ty
250 We conducted a
single-blinded,
randomized, controlled trial comparing h
251 Single-blinded rating of the exenatide group suggested c
252 ized, placebo-controlled study with a 2-week
single-blind run-in period to determine baseline severit
253 After a
single-blind run-in period, we assigned patients, in a d
254 bset of 10 521 patients entering sequential,
single-blind run-in periods (enalapril 10 mg twice daily
255 urpose of this study was to examine TBE in a
single-blind,
sham procedure randomized trial.
256 misphere) was tested in a series of separate
single-blind,
Sham-controlled crossover trials, each inc
257 In this international, prospective,
single-blinded,
sham-controlled trial, done at 44 study
258 herapy II (MNPDT-II) study was a randomized,
single-blinded,
split-face controlled, 2-arm clinical tr
259 We found that our
single blind study using eight liver tissue-specific gen
260 A multicentre, prospective, and
single blind study was performed in three European Hospi
261 TTING, AND PATIENTS: Randomized, controlled,
single-blind study conducted between January 2, 2006, an
262 A new method is tested in a
single-blind study for detection, attribution, and quant
263 We performed a multi-center, parallel,
single-blind study of 75 patients who met Rome III crite
264 In a
single-blind study performed at 2 referral centers we as
265 In total, 52 methods were used in the
single-blind study to determine method accuracy and comp
266 In a prospective, single-center,
single-blind study, 44 (of 139 screened, 31.7%) ACS pati
267 In a prospective, single-center,
single-blind study, 55 out of 117 (47%) screened consecu
268 re enrolled in this prospective, randomized,
single-blind study, employing a split-scalp design, comp
269 a randomized, placebo-controlled, crossover,
single-blinded study (subject) placebo once and 3.0 pmol
270 o August 2015, this randomized, prospective,
single-blinded study compared 2 groups (a TAP block and
271 ) is a multicenter, prospective, randomized,
single-blinded study designed to demonstrate a reduction
272 aged 6 mo were enrolled in this randomized,
single-blinded study for 9 mo, designed primarily to ass
273 A prospective, single-center, randomized,
single-blinded study from July 2009 through February 201
274 This prospective, multicenter,
single-blinded study of 232 patients (age 53 +/- 10 year
275 Nonrandomized,
single-blinded study using an interrupted time-series de
276 During
single-blind testing, the spectrometer is placed >1 km f
277 In this randomized,
single-blind,
three-group trial conducted in six countri
278 Study 2 consisted of 9 weeks of
single-blind treatment with rilonacept (part A), followe
279 he ANOSEAN study was a randomized controlled
single-blind trial (CPP 2009-A00346-51).
280 We performed a
single-blind trial at 11 hospitals in Spain from May 201
281 As a proof of concept, using a
single-blind trial design, we evaluated the progress of
282 We did a prospective randomised
single-blind trial involving patients with large pleural
283 mes (VAST-D) study, a multisite, randomized,
single-blind trial of 1,522 Veterans Health Administrati
284 We performed a
single-blind trial of 52 patients with quiescent Crohn's
285 We undertook a
single-blind trial to assess this approach.
286 We conducted an exploratory, randomized,
single-blind trial to evaluate the efficacy and safety o
287 A parallel randomized
single-blind trial was conducted in a primary care outpa
288 Pilot
single-blind trial.
289 FA is a prospective, multicenter, randomized
single-blinded trial (Randomized Trial of IN.PACT Admira
290 nal Institutes of Health-funded, randomized,
single-blinded trial conducted in 12 centers in the Unit
291 In this multicenter, randomized,
single-blinded trial, CF-RF and 2 different regimens of
292 nnual doses of IA (n = 52) in an open-label,
single-blinded trial.
293 annual doses of IA (N=52) in an open-label,
single-blinded trial.
294 was a prospective, randomized, multicenter,
single-blinded trial.
295 n 40 patients with diabetes in a randomized,
single-blind,
triple-crossover study.
296 We did a
single-blind,
two-arm, cluster-randomised controlled tri
297 A multicenter, randomized,
single-blind,
two-arm, parallel Phase-3 study was conduc
298 NATE Pivotal Study (Prospective, Randomized,
Single-Blind,
U.S. Multi-Center Study to Evaluate Treatm
299 We conducted a
single-blind,
unmatched, cluster-randomized intervention
300 We conducted a
single-blinded,
wait-list randomized controlled trial of